iCAD (ICAD) 10-Q 4 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 03, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	ICAD
Entity Registrant Name	ICAD INC
Entity Central Index Key	749,660
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		15,730,518

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 17,536	$ 32,220
Trade accounts receivable, net of allowance for doubtful accounts of $377 in 2015 and $203 in 2014	8,481	9,642
Inventory, net	3,746	2,214
Prepaid expenses and other current assets	684	540
Total current assets	30,447	44,616
Property and equipment, net of accumulated depreciation of $5,135 in 2015 and $4,861 in 2014	2,605	4,255
Other assets	94	132
Intangible assets, net of accumulated amortization of $10,694 in 2015 and $14,738 in 2014	4,473	17,504
Goodwill	14,198	27,263
Total assets	51,817	93,770
Current liabilities:
Accounts payable	1,557	2,151
Accrued and other expenses	4,142	5,554
Interest payable		180
Notes and lease payable - current portion	1,157	5,044
Deferred revenue	8,020	9,120
Total current liabilities	14,876	22,049
Deferred revenue, long-term portion	1,438	1,525
Other long-term liabilities	661	795
Capital lease - long-term portion	245	1,020
Notes payable - long-term portion		5,602
Total liabilities	$ 17,220	$ 30,991
Commitments and Contingencies (Note 6 and 8)
Stockholders' equity:
Preferred stock, $.01 par value: authorized 1,000,000 shares; none issued.
Common stock, $.01 par value: authorized 20,000,000 shares; issued 15,916,349 in 2015 and 15,732,177 in 2014; outstanding 15,730,518 in 2015 and 15,546,346 in 2014	$ 159	$ 157
Additional paid-in capital	210,961	209,100
Accumulated deficit	(175,108)	(145,063)
Treasury stock at cost, 185,831 shares in 2015 and 2014	(1,415)	(1,415)
Total stockholders' equity	34,597	62,779
Total liabilities and stockholders' equity	$ 51,817	$ 93,770

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 377	$ 203
Property and equipment, accumulated depreciation and amortization	5,135	4,861
Intangible assets, accumulated amortization	$ 10,694	$ 14,738
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	15,916,349	15,732,177
Common stock, shares outstanding	15,730,518	15,546,346
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Products	$ 4,515	$ 4,603	$ 11,569	$ 14,106
Service and supplies	5,067	7,969	22,376	16,653
Total revenue	9,582	12,572	33,945	30,759
Cost of revenue:
Products	1,110	1,019	2,731	3,589
Service and supplies	1,362	1,859	5,722	4,038
Amortization and depreciation	289	527	1,431	1,201
Total cost of revenue	2,761	3,405	9,884	8,828
Gross profit	6,821	9,167	24,061	21,931
Operating expenses:
Engineering and product development	2,093	2,086	6,621	5,952
Marketing and sales	2,697	3,448	9,692	8,912
General and administrative	2,118	2,282	6,661	5,836
Amortization and depreciation	257	425	1,373	931
Goodwill and long-lived asset impairment			27,443
Total operating expenses	7,165	8,241	51,790	21,631
Income (loss) from operations	(344)	926	(27,729)	300
Loss from extinguishment of debt			(1,723)	(903)
Gain from change in fair value of warrant		0		1,835
Interest expense	(46)	(647)	(623)	(2,078)
Other income	4	11	18	27
Other expense, net	(42)	(636)	(2,328)	(1,119)
Income (loss) before income tax (expense) benefit	(386)	290	(30,057)	(819)
Tax (expense) benefit	(16)	(16)	12	(94)
Net income (loss) and comprehensive income (loss)	$ (402)	$ 274	$ (30,045)	$ (913)
Net (loss) income per share:
Basic	$ (0.03)	$ 0.02	$ (1.92)	$ (0.07)
Diluted	$ (0.03)	$ 0.02	$ (1.92)	$ (0.07)
Weighted average number of shares used in computing loss (income) per share:
Basic	15,725	15,283	15,670	13,609
Diluted	15,725	16,348	15,670	13,609

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flow from operating activities:
Net loss	$ (30,045)	$ (913)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	1,565	1,312
Depreciation	1,239	820
Bad debt provision	341	27
Stock-based compensation expense	1,601	966
Amortization of debt discount and debt costs	337	908
Interest on settlement obligations	124	161
Loss on extinguishment of debt	1,723	903
Gain from change in fair value of warrant		(1,835)
Goodwill and long-lived asset impairment	27,443
Loss on disposal of assets	125
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	821	(2,665)
Inventory	(1,418)	(140)
Prepaid and other current assets	(197)	(26)
Accounts payable	(593)	(245)
Accrued expenses	(1,904)	142
Deferred revenue	(1,187)	437
Total adjustments	30,020	765
Net cash used for operating activities	(25)	(148)
Cash flow from investing activities:
Additions to patents, technology and other	(37)	(59)
Additions to property and equipment	(889)	(630)
Acquisition of Radion Inc, and DermEbx		(3,482)
Acquisition of VuComp M-Vu Breast Density	(1,700)
Net cash used for investing activities	(2,626)	(4,171)
Cash flow from financing activities:
Issuance of common stock for cash, net		28,214
Stock option exercises	349	616
Warrant exercise		1,575
Taxes paid related to restricted stock issuance	(87)	(110)
Principal payments of capital lease obligations	(1,045)	(313)
Principal repayment of debt financing, net	(11,250)	(4,100)
Net cash provided by (used for) financing activities	(12,033)	25,882
Increase (decrease) in cash and equivalents	(14,684)	21,563
Cash and equivalents, beginning of period	32,220	11,880
Cash and equivalents, end of period	17,536	33,443
Supplemental disclosure of cash flow information:
Interest paid	521	1,343
Taxes paid	$ 101	125
Non-cash items from investing and financing activities:
Settlement of warrant liability with purchase of common stock		2,151
Issuance of common stock related to acquisition of Radion, Inc and DermEbx		$ 8,556

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 - Basis of Presentation and Significant Accounting Policies The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2015, the results of operations of the Company for the three and nine month periods ended September 30, 2015 and 2014, and cash flows of the Company for the nine month periods ended September 30, 2015 and 2014. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10–K for the fiscal year ended December 31, 2014 filed with the SEC on March 13, 2015. The results for the three and nine month period ended September 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015, or any future period. Revenue Recognition The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue from the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable. The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered. Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale. Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs. Medical Device Excise tax included in the cost of revenue is approximately $131,000 and $462,000, for the three and nine months ended September 30, 2015, respectively and $211,000 and $590,000 for the three and nine months ended September 30, 2014, respectively. Segments The Company reports the results of two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products. The Therapy segment consists of our radiation therapy (“Axxent”) products, physics and management services, development fees, supplies, and the right to use the AxxentHub software platform.

Loss per Common Share

Loss per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Loss per Common Share	Note 2 - Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Net loss $ (402 ) $ 274 $ (30,045 ) $ (913 ) Basic and diluted shares used in the calculation of net loss per share 15,725 15,283 15,670 13,609 Effect of dilutive securities: Stock options — 756 — — Restricted stock — 309 — — Diluted shares used in the calculation of net loss per share 15,725 16,348 15,670 13,609 Net loss per share - basic and diluted $ (0.03 ) $ 0.02 $ (1.92 ) $ (0.07 ) Net loss per share - diluted $ (0.03 ) $ 0.02 $ (1.92 ) $ (0.07 ) The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows: Nine Months Ended September 30, 2015 2014 Stock Options 894,306 55,463 Restricted Stock 432,479 — Stock options and restricted stock 1,326,785 55,463

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Combinations	Note 3 – Business Combinations Acquisition of VuComp M-Vu Breast Density Product On April 29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp’s M-Vu Breast Density product for $1,700,000 in cash. The Company considered the acquisition to be an acquisition of a business as the Company acquired the Breast Density product and certain customer liabilities which were considered to be an integrated set of activities at acquisition. Under the terms of the agreement, the Company acquired the breast density intellectual property product, which has been integrated with the Company’s PowerLook Advanced Mammography Platform (AMP). PowerLook AMP is a modular solution designed to provide advanced tools for breast disease detection and analysis, including CAD for tomosynthesis. As the Company considered this to be a business combination, the assets were valued in accordance with ASC Topic 805, “ Business Combinations The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount Estimated Amortizable Life Developed Technology 900 8 years 9 months Goodwill 800 Purchase price $ 1,700 The assets obtained in the acquisition of VuComp’s M-Vu Breast Density product and the anticipated future revenues are included in the Detection segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Detection segment. Acquisition of DermEbx and Radion On July 15, 2014, the Company entered into two Asset Purchase Agreements, one with Radion, Inc. (“Radion”) the other with DermEbx, a series of Radion Capital Partners LLC (“DermEbx”) (the “Radion/DermEbx Acquisition”). Pursuant to the Asset Purchase Agreement with DermEbx, the Company purchased substantially all of the assets of DermEbx, including all of DermEbx’s intellectual property and customer contracts. The Company paid the following consideration to DermEbx: (i) $1,600,000 in cash and (ii) 600,000 restricted shares of the Company’s common stock, $0.01 par value per share. The 600,000 restricted shares were subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares were to be locked up for a period of 24 months from the date of the agreement; and 30% of the shares were to be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15%, or 90,000, of the restricted shares to US Bank, N.A., as escrow agent, which were to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares acted as the source of payment for the indemnification of the Company by DermEbx under the DermEbx Asset Purchase Agreement. On October 7, 2015, the Company and each of Radion and DermEbx entered into a working capital settlement agreement pursuant to which the restrictions on the shares were lifted, the escrow shares were released from escrow and the parties agreed to settle all amounts owed under the Asset Purchase Agreements. Pursuant to the terms of the Asset Purchase Agreement with Radion, the Company purchased substantially all of the assets of Radion, including all of Radion’s intellectual property and customer contracts. The Company paid the following consideration to Radion: (i) $2,382,000 in cash which included $182,000 payoff of an existing note payable and (ii) the issuance to Radion of 600,000 restricted shares of the Company’s common stock. The 600,000 restricted shares were subject to the following provisions; 25% of the shares were locked up until the date that was two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares were to be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15% or 90,000 of the restricted shares to US Bank, N.A., as escrow agent, which were to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares acted as the source of payment for the indemnification of the Company by Radion under the Radion Asset Purchase Agreement. On October 7, 2015, the Company and each of Radion and DermEbx entered into a working capital settlement agreement pursuant to which the restrictions on the shares were lifted, the escrow shares were released from escrow and the parties agreed to settle all amounts owed under the Asset Purchase Agreements. Prior to the Radion DermEbx Acquisition in July 2014, the Sellers represented one of the Company’s significant customers in the Therapy segment. The Company recognized approximately $0.5 million of Therapy service revenue, for a total of $2.1 million related to Sellers, in the six months ended June 30, 2014, and these amounts are included in the results for the nine months ended September 30, 2014. The amounts allocated to purchased and developed software, customer relationships, trade names, employee non-compete agreements and backlog were estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under these methods include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. Acquired intangible assets are being amortized over the estimated useful lives as set forth in the following table. The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets: Amount Estimated Amortizable Life Current assets $ 3,457 Property and equipment 2,625 3 – 7 Years Identifiable intangible assets 6,050 5 – 10 Years Goodwill 6,270 Current liabilities (4,382 ) Long-term liabilities (2,164 ) Purchase price $ 11,856 The assets obtained in the Radion/DermEbx Acquisition and the resulting revenues are included in the Therapy segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Therapy segment. As discussed in Note 12, the Company recorded a goodwill impairment charge related to the Therapy segment of $14.0 million in the quarter ended June 30, 2015. The goodwill is deductible for income tax purposes.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Note 4 – Inventory The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows: as of September 30, as of December 31, Raw materials $ 2,488 $ 955 Work in process 161 54 Finished Goods 1,097 1,205 Inventory $ 3,746 $ 2,214

Long Term Debt

Long Term Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long Term Debt	Note 5 – Long Term Debt On March 31, 2015, the Company repaid in full the aggregate amount outstanding under the Deerfield Facility Agreement, dated as of December 29, 2011 (as amended, supplemented or otherwise modified to the date hereof, the “Facility Agreement”), by and among the Company, Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., and Deerfield Special Situations Fund, L.P. and, for itself and as assignee of the obligations held by Deerfield Special Situations Fund International Master Fund, L.P. The Facility Agreement and related documents were terminated as of March 31, 2015. The Facility Agreement was to mature on December 29, 2016 and was able to be repaid prior to the maturity date at the Company’s option without penalty or premium. On March 31, 2015, the Company used cash on hand to pay the $11.25 million outstanding principal amount due under the Facility Agreement and approximately $162,000 in accrued and unpaid interest on such principal amount. The Company recorded a loss on the extinguishment of debt of approximately $1.7 million at the termination date in the quarter ended March 31, 2015. The following amounts compose interest expense included in our consolidated statement of operations for the three and nine months ended September 30, 2015 and 2014: (in thousands) Three months ended September 30, 2015 2014 Cash interest expense $ — $ 215 Non-cash amortization of debt discount — 327 Amortization of debt costs — 17 Amortization of settlement obligations 32 55 Interest expense capital lease 14 33 Total interest expense $ 46 $ 647 Nine months ended September 30 2015 2014 Cash interest expense $ 162 $ 1,009 Non-cash amortization of debt discount 254 775 Amortization of debt costs 13 93 Amortization of settlement obligations 124 161 Interest expense capital lease 70 40 Total interest expense $ 623 $ 2,078 Cash interest expense represents the amount of interest paid in cash under the Facility Agreement which represents the interest of 5.75% on the Facility Agreement through March 31, 2015. Non-cash amortization is the amortization of the discount on the Facility Agreement. The amortization of debt costs relates to the costs incurred with the financing, which is primarily a facility fee and a finder’s fee that were capitalized and are being expensed using the effective interest method. The amortization of the settlement obligation represents the interest associated with the settlement agreements for both Carl Zeiss Meditec AG and Hologic, Inc (see Note 8). Interest expense capital lease represents interest related to the capital lease as described in Note 6.

Lease Commitments

Lease Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 6 – Lease Commitments Operating leases Facilities are leased under operating leases expiring at various dates through September, 2017. Certain of these leases contain renewal options. Rent expense under operating leases was $165,000 and $490,000 for the three and nine month period ended September 30, 2015 and $150,000 and $476,000 for the three and nine month period ended September 30, 2014, respectively. Future minimum lease payments as of September 30, 2015 under operating leases are as follows: (in thousands) Fiscal Year Operating Leases 2015 $ 128 2016 499 2017 255 $ 882 Capital leases The Company entered into a capital lease agreement for the purchase of certain equipment in August 2013 for approximately $409,000. Under the guidance of ASC Topic 840, “ Leases In connection with the Radion/DermEbx Acquisition, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of September 30, 2015, the outstanding liability for the acquired equipment leases was approximately $1.4 million. Future minimum lease payments under all outstanding capital leases are as follows: (in thousands) Fiscal Year Capital 2015 $ 386 2016 1,039 2017 89 Subtotal minimum lease obligation 1,514 Less interest (112 ) Total, net 1,402 Less current portion (1,157 ) Long term portion $ 245 Kamal Gogineni is an employee of the Company’s and a beneficial owner of more than 5% of the Company’s common stock. Additionally, Mr. Gogineni is a significant shareholder of Radion Capital Partners (“RCP”). RCP was the lessor under a lease between RCP and DermEbx (the “Lease”). In connection with the Company’s Radion/DermEbx acquisition that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company is obligated to pay a total of $664,000 as of September 30, 2015 and the liability is included in the minimum lease payments above, with annual payments of $192,000 for the remainder of 2015, $396,000 in 2016 and $76,000 in 2017.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 7 - Stock-Based Compensation The Company follows the guidance in ASC Topic 718, “ Compensation – Stock Compensation , The Company granted 40,000 and 358,000 options in the three and nine months ended September 30, 2015. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Average risk-free interest rate 1.06% 0.93% 0.95% 0.84% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 74.6% 66.3% to 69.3% 60.5% to 74.6% 64.2% to 69.3% Weighted average exercise price $3.85 $8.74 $6.62 $8.02 Weighted average fair value $2.02 $4.29 $3.19 $3.80 The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Cost of revenue $ 4 $ 3 $ 11 $ 10 Engineering and product development 53 43 165 126 Marketing and sales 162 97 495 237 General and administrative 318 217 930 593 $ 537 $ 360 $ 1,601 $ 966 As of September 30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows: Remaining expense $ 4,039 Weighted average term 1.21 years The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Period Ended Aggregate intrinsic value 2015 2014 Stock options $ 584 $ 7,448 Restricted stock 1,470 3,047 The intrinsic value of stock options exercised during the nine months ended September 30, 2015 and 2014 was $0.3 million and $0.9 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies Foreign Tax Claim In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010 the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The Company believes that it is not liable for the re-assessment against CADx Medical and no accrual has been recorded for this matter as of September 30, 2015. Settlement Obligations In connection with the acquisition of Xoft in 2010, the Company recorded a royalty obligation pursuant to a settlement agreement entered into between Xoft and Hologic in August 2007. Xoft received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return, the Company has a remaining obligation to pay a minimum annual royalty payment to Hologic, of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provided for payment of royalties based upon a specified percentage of future net sales on any products that utilize the licensed rights. The Company has a liability within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations totaling $408,000. The Company recorded interest expense of approximately $19,000 and $55,000 in the three and nine months ended September 30, 2015 and $27,000 and $77,000 in the three and six months ended September 30, 2014, respectively, related to this obligation. In December, 2011, the Company agreed to a settlement related to litigation with Carl Zeiss Meditec AG. The Company is obligated to pay the remaining amount of $0.5 million in June 2017. As of September 30, 2015, the remaining liability recorded within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations is $408,000. The Company recorded interest expense of approximately $13,000 and $69,000 in the three and nine months ended September 30, 2015 and $28,000 and $84,000 in the three and nine months ended September 30, 2014, respectively, related to this obligation. Other Commitments The Company is obligated to pay approximately $2.3 million for firm purchase obligations to suppliers for future product deliverables. Litigation The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9 - Fair Value Measurements The Company follows the provisions of ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2014 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 26,530 $ — $ — $ 26,530 Total Assets $ 26,530 $ — $ — $ 26,530 Fair value measurements using: (000’s) as of September 30, 2015 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 13,573 $ — $ — $ 13,573 Total Assets $ 13,573 $ — $ — $ 13,573 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. The Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note 11 and Note 12 and re-measured long-lived assets and goodwill of the Therapy reporting unit at fair value as of the impairment date as noted in the following table. The fair values of long-lived assets and goodwill were measured using Level 3 inputs. Fair value measurements using: (000’s) as of September 30, 2015 Level 1 Level 2 Level 3 Total Non-recurring assets Long-lived and intangible assets $ — $ — $ 3,195 $ 3,195 Goodwill — — 5,735 5,735 Total Assets $ — $ — $ 8,930 $ 8,930

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 - Income Taxes The Company recorded an income tax provision of $16,000 and an income tax benefit of $12,000, in the three and nine months ended September 30, 2015 as compared to a provision of $16,000 and $94,000 in the three and nine months ended September 30, 2014, respectively. The income tax provision for the three months ended September 30, 2015 relates primarily to state taxes. The income tax net benefit for the nine months ended September 30, 2015 primarily relates to a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill, offset by the state tax provision. Due to the Company’s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At September 30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.

Long-lived assets

Long-lived assets	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 11 – Long-lived assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the “Asset Group” to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities. In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group’s) fair value. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June 30, 2015 and as a result the long lived assets in the asset group were recorded at their current fair values. A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 12 - Goodwill In accordance with FASB ASC Topic 350-20, “Intangibles - Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer (“CEO”). The two segments and reporting units are Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company performed the annual impairment assessment at October 1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company’s next annual impairment assessment is October 1, 2015. An impairment charge is recorded if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of the reporting unit. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. As a result of external factors and general uncertainty related to reimbursement for non-melanoma skin cancer and in conjunction with the long-lived asset impairment testing, the Company performed an impairment assessment of the Therapy reporting unit as of June 30, 2015. As a result the Company recorded a goodwill impairment charge of $14.0 million during the quarter ended June 30, 2015. The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships, trade-names, and the Company’s workforce. The allocation process was performed only for purposes of testing goodwill for impairment. The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results. The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit. The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million. As discussed in Note 3, the Company acquired VuComp’s M-Vu® Breast Density product for $1.7 million. The product will be integrated into the Company’s Powerlook AMP system, which is a component of the Detection reporting unit. The Company determined that the acquisition was a business combination and accordingly recorded goodwill of $0.8 million. A roll forward of goodwill activity by reporting unit is as follows: Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Balance at December 31, 2014 7,663 19,600 27,263 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at September 30, 2015 $ 8,463 $ 5,735 $ 14,198

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Reporting	Note 13 – Segment Reporting In accordance with FASB Topic ASC 280, “ Segments The Company’s CODM is the CEO. Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy. The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy Axxent products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (“Adjusted EBITDA”) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues. Our CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment revenues: Detection $ 5,202 $ 4,936 $ 14,945 $ 13,943 Therapy 4,380 7,636 19,000 16,816 Total Revenue $ 9,582 $ 12,572 $ 33,945 $ 30,759 Segment gross profit: Detection $ 4,423 $ 4,102 $ 12,460 $ 11,426 Therapy 2,398 5,065 11,601 10,505 Segment gross profit $ 6,821 $ 9,167 $ 24,061 $ 21,931 Segment operating income (loss): Detection 2,392 2,142 6,185 5,555 Therapy (558 ) 1,127 (27,070 ) 759 Segment operating income $ 1,834 $ 3,269 $ (20,885 ) $ 6,314 General, administrative, depreciation and amortization expense $ (2,178 ) $ (2,343 ) $ (6,844 ) $ (6,014 ) Interest expense (46 ) (647 ) (623 ) (2,078 ) Gain on fair value of warrant — 0 — 1,835 Other income 4 11 18 27 Loss on debt extinguishment — — (1,723 ) (903 ) Loss before income tax $ (386 ) $ 290 $ (30,057 ) $ (819 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
Text Block [Abstract]
Recent Accounting Pronouncements	Note 14 - Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (ASU 2014-09), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In April 2015 the FASB voted to defer the effective date of this standard to years beginning after December 15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue from the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable. The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered. Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.
Cost of Revenue	Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs. Medical Device Excise tax included in the cost of revenue is approximately $131,000 and $462,000, for the three and nine months ended September 30, 2015, respectively and $211,000 and $590,000 for the three and nine months ended September 30, 2014, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (ASU 2014-09), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In April 2015 the FASB voted to defer the effective date of this standard to years beginning after December 15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.
Long-lived Assets	Long-lived assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the “Asset Group” to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities. In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group’s) fair value. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June 30, 2015 and as a result the long lived assets in the asset group were recorded at their current fair values. A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.
Leases	Under the guidance of ASC Topic 840, “ Leases
Compensation - Stock Compensation	The Company follows the guidance in ASC Topic 718, “ Compensation – Stock Compensation ,
Litigation	Litigation The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.
Fair Value Measurement and Disclosures	Fair Value Measurements The Company follows the provisions of ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.
Income Taxes	The Company recorded an income tax provision of $16,000 and an income tax benefit of $12,000, in the three and nine months ended September 30, 2015 as compared to a provision of $16,000 and $94,000 in the three and nine months ended September 30, 2014, respectively. The income tax provision for the three months ended September 30, 2015 relates primarily to state taxes. The income tax net benefit for the nine months ended September 30, 2015 primarily relates to a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill, offset by the state tax provision. Due to the Company’s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At September 30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.
Intangibles - Goodwill and Other	In accordance with FASB ASC Topic 350-20, “Intangibles - Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.
Segments	In accordance with FASB Topic ASC 280, “ Segments

Loss per Common Share (Tables)

Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Calculation of Net Loss per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Net loss $ (402 ) $ 274 $ (30,045 ) $ (913 ) Basic and diluted shares used in the calculation of net loss per share 15,725 15,283 15,670 13,609 Effect of dilutive securities: Stock options — 756 — — Restricted stock — 309 — — Diluted shares used in the calculation of net loss per share 15,725 16,348 15,670 13,609 Net loss per share - basic and diluted $ (0.03 ) $ 0.02 $ (1.92 ) $ (0.07 ) Net loss per share - diluted $ (0.03 ) $ 0.02 $ (1.92 ) $ (0.07 )
Exercise of Stock Options and Vesting of Restricted Stock	The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows: Nine Months Ended September 30, 2015 2014 Stock Options 894,306 55,463 Restricted Stock 432,479 — Stock options and restricted stock 1,326,785 55,463

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2015
VuComp M-Vu Breast Density Product [Member]
Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount Estimated Amortizable Life Developed Technology 900 8 years 9 months Goodwill 800 Purchase price $ 1,700
DermEbx and Radion [Member]
Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets: Amount Estimated Amortizable Life Current assets $ 3,457 Property and equipment 2,625 3 – 7 Years Identifiable intangible assets 6,050 5 – 10 Years Goodwill 6,270 Current liabilities (4,382 ) Long-term liabilities (2,164 ) Purchase price $ 11,856

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows: as of September 30, as of December 31, Raw materials $ 2,488 $ 955 Work in process 161 54 Finished Goods 1,097 1,205 Inventory $ 3,746 $ 2,214

Long Term Debt (Tables)

Long Term Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Interest Expense Included in Consolidated Income Statement	The following amounts compose interest expense included in our consolidated statement of operations for the three and nine months ended September 30, 2015 and 2014: (in thousands) Three months ended September 30, 2015 2014 Cash interest expense $ — $ 215 Non-cash amortization of debt discount — 327 Amortization of debt costs — 17 Amortization of settlement obligations 32 55 Interest expense capital lease 14 33 Total interest expense $ 46 $ 647 Nine months ended September 30 2015 2014 Cash interest expense $ 162 $ 1,009 Non-cash amortization of debt discount 254 775 Amortization of debt costs 13 93 Amortization of settlement obligations 124 161 Interest expense capital lease 70 40 Total interest expense $ 623 $ 2,078

Lease Commitments (Tables)

Lease Commitments (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Operating Leases	Future minimum lease payments as of September 30, 2015 under operating leases are as follows: (in thousands) Fiscal Year Operating 2015 $ 128 2016 499 2017 255 $ 882
Future Minimum Lease Payments under Non-cancelable Capital Leases	Future minimum lease payments under all outstanding capital leases are as follows: (in thousands) Fiscal Year Capital 2015 $ 386 2016 1,039 2017 89 Subtotal minimum lease obligation 1,514 Less interest (112 ) Total, net 1,402 Less current portion (1,157 ) Long term portion $ 245

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Average risk-free interest rate 1.06% 0.93% 0.95% 0.84% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 74.6% 66.3% to 69.3% 60.5% to 74.6% 64.2% to 69.3% Weighted average exercise price $3.85 $8.74 $6.62 $8.02 Weighted average fair value $2.02 $4.29 $3.19 $3.80
Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense	The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Cost of revenue $ 4 $ 3 $ 11 $ 10 Engineering and product development 53 43 165 126 Marketing and sales 162 97 495 237 General and administrative 318 217 930 593 $ 537 $ 360 $ 1,601 $ 966
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period	As of September 30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows: Remaining expense $ 4,039 Weighted average term 1.21 years
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Period Ended Aggregate intrinsic value 2015 2014 Stock options $ 584 $ 7,448 Restricted stock 1,470 3,047

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2014 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 26,530 $ — $ — $ 26,530 Total Assets $ 26,530 $ — $ — $ 26,530 Fair value measurements using: (000’s) as of September 30, 2015 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 13,573 $ — $ — $ 13,573 Total Assets $ 13,573 $ — $ — $ 13,573
Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs	The fair values of long-lived assets and goodwill were measured using Level 3 inputs. Fair value measurements using: (000’s) as of September 30, 2015 Level 1 Level 2 Level 3 Total Non-recurring assets Long-lived and intangible assets $ — $ — $ 3,195 $ 3,195 Goodwill — — 5,735 5,735 Total Assets $ — $ — $ 8,930 $ 8,930

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Roll Forward of Goodwill Activity by Reportable Segment	A roll forward of goodwill activity by reporting unit is as follows: Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Balance at December 31, 2014 7,663 19,600 27,263 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at September 30, 2015 $ 8,463 $ 5,735 $ 14,198

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment revenues: Detection $ 5,202 $ 4,936 $ 14,945 $ 13,943 Therapy 4,380 7,636 19,000 16,816 Total Revenue $ 9,582 $ 12,572 $ 33,945 $ 30,759 Segment gross profit: Detection $ 4,423 $ 4,102 $ 12,460 $ 11,426 Therapy 2,398 5,065 11,601 10,505 Segment gross profit $ 6,821 $ 9,167 $ 24,061 $ 21,931 Segment operating income (loss): Detection 2,392 2,142 6,185 5,555 Therapy (558 ) 1,127 (27,070 ) 759 Segment operating income $ 1,834 $ 3,269 $ (20,885 ) $ 6,314 General, administrative, depreciation and amortization expense $ (2,178 ) $ (2,343 ) $ (6,844 ) $ (6,014 ) Interest expense (46 ) (647 ) (623 ) (2,078 ) Gain on fair value of warrant — 0 — 1,835 Other income 4 11 18 27 Loss on debt extinguishment — — (1,723 ) (903 ) Loss before income tax $ (386 ) $ 290 $ (30,057 ) $ (819 )

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)
Basis Of Presentation And Significant Accounting Policies [Abstract]
Medical Device Excise tax included in the cost of revenue | $	$ 131,000	$ 211,000	$ 462,000	$ 590,000
Business segment			2

Loss per Common Share - Calcula

Loss per Common Share - Calculation of Net Loss per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (402)	$ 274	$ (30,045)	$ (913)
Basic and diluted shares used in the calculation of net loss per share	15,725	15,283	15,670	13,609
Effect of dilutive securities:
Diluted shares used in the calculation of net loss per share	15,725	16,348	15,670	13,609
Net loss per share - basic and diluted	$ (0.03)	$ 0.02	$ (1.92)	$ (0.07)
Net loss per share - diluted	$ (0.03)	$ 0.02	$ (1.92)	$ (0.07)
Stock Options [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements		756
Restricted Stock [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements		309

Loss per Common Share - Exercis

Loss per Common Share - Exercise of Stock Options and Vesting of Restricted Stock (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options and restricted stock	1,326,785	55,463
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options and restricted stock	894,306	55,463
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options and restricted stock	432,479

Business Combinations - Acquisi

Business Combinations - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) - USD ($)	Apr. 29, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Business acquisition paid in cash		$ 1,700,000
VuComp M-Vu Breast Density Product [Member]
Business Acquisition [Line Items]
Business acquisition paid in cash	$ 1,700,000	$ 1,700,000
Estimated amortizable life	8 years 10 months 24 days

Business Combinations - Prelimi

Business Combinations - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) - USD ($) $ in Thousands	Apr. 29, 2015	Jul. 15, 2014	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill			$ 14,198	$ 27,263
VuComp M-Vu Breast Density Product [Member]
Business Acquisition [Line Items]
Developed Technology	$ 900
Goodwill	800		$ 800
Purchase price	$ 1,700
Estimated amortizable life	8 years 10 months 24 days
Radion Inc [Member]
Business Acquisition [Line Items]
Current assets		$ 3,457
Property and equipment		2,625
Identifiable intangible assets		6,050
Goodwill		6,270
Current liabilities		(4,382)
Long-term liabilities		(2,164)
Purchase price		$ 11,856
Minimum [Member] | Radion Inc [Member]
Business Acquisition [Line Items]
Property and equipment, Estimated amortizable life		3 years
Estimated amortizable life		5 years
Maximum [Member] | Radion Inc [Member]
Business Acquisition [Line Items]
Property and equipment, Estimated amortizable life		7 years
Estimated amortizable life		10 years

Business Combinations - Acqui35

Business Combinations - Acquisition of DermEbx and Radion - Additional Information (Detail) - USD ($)	Jul. 15, 2014	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Business acquisition paid in cash						$ 1,700,000
Common stock, par value		$ 0.01				$ 0.01		$ 0.01
Revenue from services		$ 5,067,000		$ 7,969,000		$ 22,376,000	$ 16,653,000
Total revenue		9,582,000		12,572,000		33,945,000	30,759,000
Impairment loss						13,981,000
Cancer Therapy [Member]
Business Acquisition [Line Items]
Total revenue		$ 4,380,000		$ 7,636,000		19,000,000	$ 16,816,000
Impairment loss			$ 13,981,000			13,981,000
Prior to Radion DermEbx Acquisition [Member] | Cancer Therapy [Member]
Business Acquisition [Line Items]
Revenue from services					$ 500,000	500,000
Total revenue					$ 2,100,000	$ 2,100,000
Radion Inc [Member]
Business Acquisition [Line Items]
Business acquisition paid in cash	$ 2,382,000
Restricted shares provisions description						The 600,000 restricted shares were subject to the following provisions; 25% of the shares were locked up until the date that was two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares were to be locked up for a period of 36 months from the date of the agreement.
Percentage of restricted shares held in escrow	15.00%
Restricted shares held in escrow	90,000
Restricted shares held in escrow, period	18 months
Repayment of note payable	$ 182,000
Radion Inc [Member] | Restricted Stock [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition restricted shares issued	600,000
DermEbx [Member]
Business Acquisition [Line Items]
Business acquisition paid in cash	$ 1,600,000
Restricted shares provisions description						The 600,000 restricted shares were subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares were to be locked up for a period of 24 months from the date of the agreement; and 30% of the shares were to be locked up for a period of 36 months from the date of the agreement.
Percentage of restricted shares held in escrow	15.00%
Restricted shares held in escrow	90,000
Restricted shares held in escrow, period	18 months
DermEbx [Member] | Restricted Stock [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 0.01
DermEbx [Member] | Restricted Stock [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition restricted shares issued	600,000

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 2,488	$ 955
Work in process	161	54
Finished Goods	1,097	1,205
Inventory	$ 3,746	$ 2,214

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail) - USD ($)	Mar. 31, 2015	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Payment of accrued and unpaid interest			$ 521,000	$ 1,343,000
Repayment of debt			11,250,000	4,100,000
Loss on extinguishment of debt		$ (1,700,000)	$ (1,723,000)	$ (903,000)
Facility Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Dec. 29, 2016
Payment of accrued and unpaid interest	$ 162,000
Repayment of debt	$ 11,250,000
Interest on facility agreement	5.75%	5.75%

Long Term Debt - Interest Expen

Long Term Debt - Interest Expense Included in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Interest Expense, Debt [Abstract]
Cash interest expense		$ 215	$ 162	$ 1,009
Non-cash amortization of debt discount		327	254	775
Amortization of debt costs		17	13	93
Amortization of settlement obligations	$ 32	55	124	161
Interest expense capital lease	14	33	70	40
Total interest expense	$ 46	$ 647	$ 623	$ 2,078

Lease Commitments - Additional

Lease Commitments - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)LeaseContracts	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Aug. 31, 2013USD ($)
Schedule Of Leases [Line Items]
Rent expense under operating leases	$ 165,000	$ 150,000	$ 490,000	$ 476,000
Operating leases expiring description			Facilities are leased under operating leases expiring at various dates through September, 2017.
Capital lease						$ 409,000
Capital lease bargain purchase option amount						$ 1
Outstanding liability on equipment leases	245,000		$ 245,000		$ 1,020,000
Annual lease payments, remainder of 2015	386,000		386,000
Annual lease payments in 2016	1,039,000		1,039,000
Annual lease payments in 2017	89,000		89,000
Total lease payments	$ 1,402,000		$ 1,402,000
Minimum [Member]
Schedule Of Leases [Line Items]
Employee stock ownership percentage	5.00%		5.00%
DermEbx and Radion [Member]
Schedule Of Leases [Line Items]
Number of equipment lease obligation | LeaseContracts			2
Assumed capital leases	$ 2,600,000		$ 2,600,000
Liability recorded on capital leases			2,500,000
Outstanding liability on equipment leases	1,400,000		1,400,000
Annual lease payments, remainder of 2015	192,000		192,000
Annual lease payments in 2016	396,000		396,000
Annual lease payments in 2017	76,000		76,000
Total lease payments	$ 664,000		$ 664,000

Lease Commitments - Future Mini

Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Leases [Abstract]
2,015	$ 128
2,016	499
2,017	255
Total	$ 882

Lease Commitments - Future Mi41

Lease Commitments - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Leases [Abstract]
2,015	$ 386
2,016	1,039
2,017	89
Subtotal minimum lease obligation	1,514
Less interest	(112)
Total, net	1,402
Less current portion	(1,157)
Long term portion	$ 245	$ 1,020

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of stock options exercised		$ 0.3	$ 0.9
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted	40,000	358,000

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	1.06%	0.93%	0.95%	0.84%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 3.85	$ 8.74	$ 6.62	$ 8.02
Weighted average fair value	$ 2.02	$ 4.29	$ 3.19	$ 3.80
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	74.60%	66.30%	60.50%	64.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		69.30%	74.60%	69.30%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Engineering and product development	$ 2,093	$ 2,086	$ 6,621	$ 5,952
Marketing and sales	2,697	3,448	9,692	8,912
General and administrative	2,118	2,282	6,661	5,836
Stock-based compensation expense	537	360	1,601	966
Operating Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Cost of revenue	4	3	11	10
Engineering and product development	53	43	165	126
Marketing and sales	162	97	495	237
General and administrative	$ 318	$ 217	$ 930	$ 593

Stock-Based Compensation - Unre

Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]
Remaining expense	$ 4,039
Weighted average term	1 year 2 months 16 days

Stock-Based Compensation - Aggr

Stock-Based Compensation - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, Stock option	$ 584	$ 7,448
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, Restricted stock	$ 1,470	$ 3,047

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended	9 Months Ended
	Feb. 28, 2010	Jul. 31, 2007	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Loss Contingencies [Line Items]
Minimum annual royalty payment						$ 250,000
Minimum royalty obligations			$ 408,000			408,000
Litigation and settlement obligation, Total			500,000			500,000
Royalty obligation non-current			408,000			408,000
Purchase obligations to suppliers for future product deliverables			2,300,000			2,300,000
CADx Medical Systems Inc. [Member]
Loss Contingencies [Line Items]
Tax re-assessment received		$ 6,800,000
Reduced tax re-assessment received	$ 703,000
Hologic [Member]
Loss Contingencies [Line Items]
Interest expense royalty obligation			19,000	$ 27,000	$ 77,000	55,000
Zeiss [Member]
Loss Contingencies [Line Items]
Interest expense royalty obligation			$ 13,000	$ 28,000		$ 69,000	$ 84,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets
Total Assets	$ 13,573	$ 26,530
Money Market Accounts [Member]
Assets
Total Assets	13,573	26,530
Level 1 [Member]
Assets
Total Assets	13,573	26,530
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 13,573	$ 26,530

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Goodwill and long-lived asset impairment	$ 27,443
Impairment loss	13,981
Impairment charges on long lived assets	$ 13,400

Fair Value Measurements - Fair

Fair Value Measurements - Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs (Detail) - Fair Value, Measurements, Nonrecurring [Member] $ in Thousands	Sep. 30, 2015USD ($)
Non-recurring assets
Total Assets	$ 8,930
Long Lived and Intangible Assets [Member]
Non-recurring assets
Total Assets	3,195
Goodwill [Member]
Non-recurring assets
Total Assets	5,735
Level 3 [Member]
Non-recurring assets
Total Assets	8,930
Level 3 [Member] | Long Lived and Intangible Assets [Member]
Non-recurring assets
Total Assets	3,195
Level 3 [Member] | Goodwill [Member]
Non-recurring assets
Total Assets	$ 5,735

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 0		$ 0
Adjustment to liabilities or tax expense			0
Interest or penalties related to uncertain tax positions	0		$ 0
Company preceding tax years			3 years
Income tax provision	$ 16,000	$ 16,000	$ (12,000)	$ 94,000

Long-lived Assets - Additional

Long-lived Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Carrying value of asset group		$ 2,605	$ 4,255
Impairment charges on long lived assets		$ 13,400
Cancer Therapy [Member]
Property, Plant and Equipment [Line Items]
Carrying value of asset group	$ 36,800
Undiscounted cash flows over carrying value of assets	2,800
Impairment charges on long lived assets	$ 13,400

Goodwill - Additional Informati

Goodwill - Additional Information (Detail)	Apr. 29, 2015USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)Segment	Dec. 31, 2014USD ($)
Goodwill [Line Items]
Number of reporting segments | Segment			2
Impairment loss			$ 13,981,000
Percentage of discount derived from capital asset pricing model			17.00%
Fair value of goodwill			$ 5,700,000
Business acquisition paid in cash			1,700,000
Goodwill			14,198,000	$ 27,263,000
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Business acquisition paid in cash	$ 1,700,000		1,700,000
Goodwill	$ 800,000		$ 800,000
Detection [Member]
Goodwill [Line Items]
Percentage of fair value of each reporting unit			315.00%
Goodwill			$ 8,463,000	7,663,000
Cancer Therapy [Member]
Goodwill [Line Items]
Percentage of fair value of each reporting unit			255.00%
Impairment loss		$ 13,981,000	$ 13,981,000
Goodwill			$ 5,735,000	$ 19,600,000

Goodwill - Roll Forward of Good

Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015
Goodwill [Line Items]
Accumulated Goodwill		$ 47,937
Accumulated impairment		(26,828)
Goodwill Balance		27,263
Acquisition measurement period adjustments		116
Impairment		(13,981)
Goodwill Balance		14,198
DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost		6,154
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost		800
Goodwill Balance		800
Detection [Member]
Goodwill [Line Items]
Fair value allocation		7,663
Goodwill Balance		7,663
Goodwill Balance		8,463
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost		800
Cancer Therapy [Member]
Goodwill [Line Items]
Fair value allocation		13,446
Goodwill Balance		19,600
Acquisition measurement period adjustments		116
Impairment	$ (13,981)	(13,981)
Goodwill Balance		5,735
Cancer Therapy [Member] | DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost		$ 6,154

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)
Schedule Of Geographical Information [Line Items]
Number of reporting segments | Segment			2
Total export sales	$ 9,582,000	$ 12,572,000	$ 33,945,000	$ 30,759,000
Intersegment Eliminations [Member]
Schedule Of Geographical Information [Line Items]
Total export sales			$ 0

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment revenues:
Total revenue	$ 9,582		$ 12,572	$ 33,945	$ 30,759
Segment gross profit:
Segment gross profit	6,821		9,167	24,061	21,931
Segment operating income (loss):
Segment operating income	1,834		3,269	(20,885)	6,314
General, administrative, depreciation and amortization expense	(2,178)		(2,343)	(6,844)	(6,014)
Interest expense	(46)		(647)	(623)	(2,078)
Gain on fair value of warrant			0		1,835
Other income	4		11	18	27
Loss on debt extinguishment		$ (1,700)		(1,723)	(903)
Income (loss) before income tax (expense) benefit	(386)		290	(30,057)	(819)
Detection [Member]
Segment revenues:
Total revenue	5,202		4,936	14,945	13,943
Segment gross profit:
Segment gross profit	4,423		4,102	12,460	11,426
Segment operating income (loss):
Segment operating income	2,392		2,142	6,185	5,555
Cancer Therapy [Member]
Segment revenues:
Total revenue	4,380		7,636	19,000	16,816
Segment gross profit:
Segment gross profit	2,398		5,065	11,601	10,505
Segment operating income (loss):
Segment operating income	$ (558)		$ 1,127	$ (27,070)	$ 759